Table 3.
Power output at the anaerobic threshold (WAT), 4 (W4) and 8 mmol (W8) in the four study groups at the baseline (T1) and after 10 weeks (T2).
| Group | T1 | T2 | P (TxG) | η2p |
|---|---|---|---|---|
| WAT (W) | ||||
| PLG | 254 ± 34 | 259 ± 20 | 0.228 | 0.168 |
| CrMG | 242 ± 21 | 253 ± 12 | ||
| HMBG | 238 ± 40 | 253 ± 35 * | ||
| CrM-HMBG | 238 ± 22 | 264 ± 19 * | ||
| W4 (W) | ||||
| PLG | 242 ± 16 | 241 ± 31 | 0.196 | 0.181 |
| CrMG | 243 ± 20 | 247 ± 21 | ||
| HMBG | 238 ± 45 | 251 ± 36 | ||
| CrM-HMBG | 236 ± 29 | 262 ± 19 * | ||
| W8 (W) | ||||
| PLG | 317 ± 19 | 314 ± 24 | <0.001 | 0.766 |
| CrMG | 300 ± 20 | 314 ± 21 * | ||
| HMBG | 295 ± 45 | 31 ± 48 * | ||
| CrM-HMBG | 288 ± 21 | 331 ± 35 * | ||
Data are expressed as mean ± standard deviation. P (TxG): group-by-time interaction (p < 0.05. All such occurrences). Two-factor repeated-measures ANOVA. *: Significantly different between study points (T1 vs. T2) p < 0.05. PLG: Placebo group; CrMG: Creatine monohydrate supplemented group; HMBG: HMB supplemented group; CrM-HMBG: Creatine monohydrate plus HMB supplemented group.